» Authors » Anand R Shewale

Anand R Shewale

Explore the profile of Anand R Shewale including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 151
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Shewale A, Poh W, Reed M, Liu J, Cadiou F, Ezzati A, et al.
Headache . 2024 Sep; 64(10):1244-1252. PMID: 39324611
Objective: To assess the real-world effectiveness of ubrogepant by evaluating self-reported satisfaction with pain relief, ability to think clearly, and return to normal function in individuals who had used ubrogepant...
2.
Shewale A, Brandenburg J, Burslem K, Lipton R, Doshi J
Cephalalgia . 2024 Feb; 44(2):3331024241235139. PMID: 38410849
Objective: Estimate health care resource utilization and costs associated with medication overuse headache and potential acute medication overuse. Methods: A retrospective analysis was conducted with Clinformatics Data Mart data (1...
3.
Lipton R, Halker Singh R, Revicki D, Zhao S, Shewale A, Lateiner J, et al.
J Headache Pain . 2022 Apr; 23(1):50. PMID: 35468729
Background: Triptans are the first-line option for the acute treatment of migraine attacks; however, triptans are contraindicated in people with certain underlying cardiovascular risk factors and are associated with inadequate...
4.
Lee J, Shewale A, Barthold D, Devine B
Headache . 2021 Nov; 61(10):1499-1510. PMID: 34841520
Objective: To assess the geographic variations in triptan and opioid prescribing patterns for patients with migraine. Background: Numerous guidelines recommend triptans as the standard of care for migraine attacks, yet...
5.
Marcus S, Shewale A, Silberstein S, Lipton R, Young W, Viswanathan H, et al.
Cephalalgia . 2020 Apr; 40(7):639-649. PMID: 32223301
Background: Triptans are the most commonly prescribed acute treatments for migraine; however, not all triptan users experience adequate response. Information on real-world resource use and costs associated with triptan insufficient...
6.
Lipton R, Marcus S, Shewale A, Dodick D, Viswanathan H, Doshi J
Cephalalgia . 2020 Mar; 40(5):437-447. PMID: 32138526
Background: Triptans are the most commonly used acute treatment for migraine. This study evaluated real-world treatment patterns following an initial triptan prescription to understand refill rates and use of non-triptan...
7.
Dodick D, Lipton R, Ailani J, Halker Singh R, Shewale A, Zhao S, et al.
Headache . 2020 Feb; 60(4):686-700. PMID: 32073660
Objective: To evaluate the efficacy of ubrogepant on patient-reported functional disability, satisfaction with study medication, and global impression of change. Background: Ubrogepant is a small-molecule, oral calcitonin gene-related peptide receptor...
8.
Pavlovic J, Yu J, Silberstein S, Reed M, Kawahara S, Cowan R, et al.
Cephalalgia . 2019 Mar; 39(4):465-476. PMID: 30854881
Objective: To develop a claims-based algorithm to identify undiagnosed chronic migraine among patients enrolled in a healthcare system. Methods: An observational study using claims and patient survey data was conducted...
9.
Brown J, Shewale A, Talbert J
J Manag Care Spec Pharm . 2017 Aug; 23(9):958-967. PMID: 28854077
Background: Few studies have assessed adherence to non-vitamin K antagonist oral anticoagulants (NOACs), especially using contemporary data now that multiple NOACs are available. Objective: To compare adherence and treatment patterns...
10.
Shewale A, Barnes C, Fischbach L, Ounpraseuth S, Painter J, Martin B
J Arthroplasty . 2017 Aug; 32(12):3591-3597.e24. PMID: 28781020
Background: Use of intra-articular hyaluronic acid (HA) injections to manage knee osteoarthritis (OA) remains controversial because of weak and conflicting evidence. The objective was to evaluate the effectiveness of intra-articular...